A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx

Vaccine

Volumn 28, Issue 13, 2010, Pages 2510-2516

  Kodama, Satoru ^a   Hirano, Takashi ^a   Noda, Kenji ^a   Abe, Nobuyuki ^a   Suzuki, Masashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Dendritic cell; Flt3 ligand; Mucosal immunity; Nasal vaccine; NTHi; P6

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD86 ANTIGEN; CD8ALPHA ANTIGEN; FLT3 LIGAND; GAMMA INTERFERON; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN P6; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCING CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; GENE EXPRESSION; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; LYMPHOID TISSUE; MOUSE; MUCOSAL IMMUNITY; NASOPHARYNX; NONHUMAN; NOSE SMEAR; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NASAL CAVITY; NASOPHARYNX;

EID: 77649180331     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.043     Document Type: Article

References (44)

1. Murphy T.F. Respiratory infections caused by non-typeable Haemophilus influenzae. Curr Opin Infect Dis 16 (2003) 129-134
2. Poolman J.T., Bakaletz L., Cripps A.W., Denoel P.A., Forsgren A., Kyd J., et al. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine 19 Suppl. (2000) S108-S115
3. Bertot G.M., Becker P.D., Guzman C.A., and Grinstein S. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis 189 (2004) 1304-1312
4. Murphy T.F., Bartos L.C., Rice P.A., Nelson M.B., Dudas K.C., and Apicella M.A. Identification of a 16,600-dalton outer membrane protein on nontypeable Haemophilus influenzae as a target for human serum bactericidal antibody. J Clin Invest 78 (1986) 1020-1027
5. Badr W.H., Loghmanee D., Karalus R.J., Murphy T.F., and Thanavala Y. Immunization of mice with P6 of nontypeable Haemophilus influenzae: kinetics of the antibody response and IgG subclasses. Vaccine 18 (1999) 29-37
6. Kyd J.M., Dunkley M.L., and Cripps A.W. Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun 63 (1995) 2931-2940
7. DeMaria T.F.D., Murwin M., and Leake E.R. Immunization with outer membrane protein P6 from nontypeable Haemophilus influenzae induces bactericidal antibody and affords protection in the chinchilla model of otitis media. Infect Immun 64 (1996) 5187-5192
8. Munson Jr. R.S., and Granoff D.M. Purification and partial characterization of outer membrane proteins P5 and P6 from Haemophilus influenzae type b. Infect Immun 49 (1985) 544-549
9. Yang T.P., Munson Jr. R.S., and Grass S. Effect of lipid modification on the physicochemical, structural, antigenic and immunoprotective properties of Haemophilus influenzae outer membrane protein P6. Vaccine 15 (1997) 976-987
10. Kiyono H., and Fukuyama S. NALT versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 4 (2004) 699-710
11. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 Suppl. (2005) S45-S53
12. Holmgren J., Czerkinsky C., Eriksson K., and Mharandi A. Mucosal immunization and adjuvants: a brief overview of recent advances and challenges. Vaccine 21 Suppl. (2003) S89-S95
13. Holmgren J., Lycke N., and Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11 (1993) 1179-1184
14. Marinaro M., Staats H.F., Hiroi T., Jackson R.J., Coste M., Boyaka P.N., et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 155 (1995) 4621-4629
15. Xu-Amano J., Jackson R.J., Fujihashi K., Kiyono H., Staats H.F., McGhee J.R., et al. Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine 12 (1994) 903-911
16. Kodama S., Suenaga S., Hirano T., Suzuki M., and Mogi G. Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization. Infect Immun 68 (2000) 2294-2300
17. Sabirov A., Kodama S., Hirano T., Suzuki M., and Mogi G. Intranasal Immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media. Infect Immun 69 (2001) 2964-2971
18. Pulendran B., Smith J.L., Caspary G., Brasel K., Pettit D., Maraskovsky E., et al. Distinct dendritic cell subset differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 96 (1999) 1036-1041
19. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
20. Shortman K., and Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2 (2002) 151-161
21. Pulendran B., Banchereau J., Maraskovsky E., and Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22 (2001) 41-47
22. Lyman S.D., James L., Vanden Bos T., de Vries P., Brasel K., Gliniak B., et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75 (1993) 1157-1167
23. Marakovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184 (1996) 1953-1962
24. Brasel K., De Smedt T., Smith J.L., and Maliszewski C.R. Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 96 (2000) 3029-3039
25. Pulendran B., Banchereau J., Burkeholder S., Kraus E., Guinet E., Chalouni C., et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 165 (2000) 566-572
26. + dendritic cells for enhanced mucosal immunity. J Immunol 172 (2004) 3612-3619
27. Pabst R., Luhrmann A., Steinmetz I., and Tschernig T. A single intratracheal dose of the growth factor fms-like tyrosine kinase receptor-3 ligand induces a rapid differential increase of dendritic cells and lymphocyte subsets in lung tissue and bronchoalveolar lavage, resulting in an increased local antibody production. J Immunol 171 (2003) 325-330
28. Abe N., Kodama S., Hirano T., Eto M., and Suzuki M. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against nontypeable Haemophilus influenzae in the nasopharynx. Laryngoscope 116 (2006) 407-412
29. Kurono Y., Shigemi H., Kodama S., and Mogi G. Effects of oral and systemic immunization on nasopharymgela clearance of nontypeable Haemophilus influenzae in BALB/c mice. Laryngoscope 106 (1996) 614-618
30. Williamson E., Westrich G.M., and Viney J.L. Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol 163 (1999) 3668-3675
31. Baca-Estrada M.E., Ewen C., Mahony D., Babiuk L.A., Wilkie D., and Foldvari M. The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology 107 (2002) 69-76
32. Fukuiwa T., Sekine S., Kobatashi R., Suzuki H., Kataoka K., Gilbert R.S., et al. A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine 26 (2008) 4849-4859
33. Pisarev V.M., Parajuli P., Mosley R.L., Sublet J., Kelsey L., Sarin P.S., et al. Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine. Int J Immunopharmacol 22 (2000) 865-876
34. Vollstedt S., Franchini M., Hefti H.P., Odermatt B., O'Keeffe M., Alber G., et al. Flt3 ligand-treated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections. J Exp Med 197 (2003) 575-584
35. Wurzenberger C., Koelzer V.H., Schreiber S., Anz D., Vollmar A.M., Schnurr M., et al. Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell response in vivo. Cancer Immunol Immunother 58 (2009) 901-913
36. Lynch D.H., Andreasen A., Maraskovsky E., Whitmore J., Miller R.E., and Schuh J.C. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3 (1997) 625-631
37. Johansson C., and Kelsall B.L. Phenotype and function of intestinal dendritic cells. Semin Immunol 17 (2005) 284-294
38. Hochrein H., Shortman K., Vremec D., Scott B., Hertzog P., and O'Keefe M. Differential production of IL-12, IFN-α, and IFN-γ by mouse dendritic cell subsets. J Immunol 166 (2001) 5448-5455
39. Iwasaki A., and Kelsall B.L. Localization of distinct Peyer's patch dendritic cells subset and their recruitment by chemokines macrophage inflammatory protein (MIP)-3α, MIP-3β, and secondary lymphoid organ chemokine. J Exp Med 191 (2000) 1381-1393
40. Mowat A.M. Dendritic cells and immune responses to orally administered antigens. Vaccine 23 (2005) 1797-1799
41. Fleeton M., Contractor N., Leon F., He J., Wetzel D., Dermody T., et al. Involvement of dendritic cell subsets in the induction of oral tolerance and immunity. Ann N Y Acad Sci 1029 (2004) 60-65
42. Finkelman F.D., Holmes J., Katona I.M., Urban Jr. J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8 (1990) 303-333
43. Marinaro M., Boyaka P.N., Finkelman F.D., Kiyono H., Jackson R.J., Jirillo E., et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 185 (1997) 415-427
44. Ramsay A.J., Husband A.J., Ramshaw I.A., Bao S., Matthaei K.I., Koehler G., et al. The role ofinterleukin-6 in mucosal IgA antibody responses in vivo. Science 264 (1994) 561-563